Cathepsin K inhibitors: A novel target for osteoporosis therapy

被引：138

作者：

Stoch, S. A. ^{[1
]}

Wagner, J. A. ^{[1
]}

机构：

[1] Merck Res Labs, Dept Clin Pharmacol, Rahway, NJ USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2008年 / 83卷 / 01期

关键词：

D O I：

10.1038/sj.clpt.6100450

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Osteoporosis is characterized by low bone mass with skeletal fragility and an increased risk of fracture. This bone loss is brought about by an imbalance between bone resorption and formation. Cathepsin K is the most abundant cysteine protease expressed in the osteoclast and is believed to be instrumental in bone matrix degradation necessary for bone resorption. Cathepsin K inhibitors represent a novel target for developing agents to treat osteoporosis and other disorders characterized by increased bone resorption.

引用

收藏

页码：172 / 176

页数：5

相关论文

共 34 条

[1]

Adami S, 2006, J BONE MINER RES, V21, pS24

[2] Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys [J].

Binkley, N ;

Kimmel, D ;

Bruner, J ;

Haffa, A ;

Davidowitz, B ;

Meng, C ;

Schaffer, V ;

Green, J .

JOURNAL OF BONE AND MINERAL RESEARCH, 1998, 13 (11) :1775-1782

[3]

Bone HG, 2007, J BONE MINER RES, V22, pS37

[4] Proteolytic activity of human osteoclast cathepsin K - Expression, purification, activation, and substrate identification [J].

Bossard, MJ ;

Tomaszek, TA ;

Thompson, SK ;

Amegadzie, BY ;

Hanning, CR ;

Jones, C ;

Kurdyla, JT ;

McNulty, DE ;

Drake, FH ;

Gowen, M ;

Levy, MA .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (21) :12517-12524

[5] INHIBITION OF OSTEOCLASTIC BONE-RESORPTION INVIVO BY ECHISTATIN, AN ARGINYL-GLYCYL-ASPARTYL (RGD)-CONTAINING PROTEIN [J].

FISHER, JE ;

CAULFIELD, MP ;

SATO, M ;

QUARTUCCIO, HA ;

GOULD, RJ ;

GARSKY, VM ;

RODAN, GA ;

ROSENBLATT, M .

ENDOCRINOLOGY, 1993, 132 (03) :1411-1413

[6]

FLANAGAN A, 1998, METHODS BONE BIOL

[7] Clinical case seminar - Decreased bone turnover and deterioration of bone structure in two cases of pycnodysostosis [J].

Fratzl-Zelman, N ;

Valenta, A ;

Roschger, P ;

Nader, A ;

Gelb, BD ;

Fratzl, P ;

Klaushofer, K .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (04) :1538-1547

[8] Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency [J].

Gelb, BD ;

Shi, GP ;

Chapman, HA ;

Desnick, RJ .

SCIENCE, 1996, 273 (5279) :1236-1238

[9] Cloning and expression of rhesus monkey cathepsin K [J].

Guay, J ;

Riendeau, D ;

Mancini, JA .

BONE, 1999, 25 (02) :205-209

[10] Cathepsin K antisense oligodeoxynucleotide inhibits osteoclastic bone resorption [J].

Inui, T ;

Ishibashi, O ;

Inaoka, T ;

Origane, Y ;

Kumegawa, M ;

Kokubo, T ;

Yamamura, T .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (13) :8109-8112

← 1 2 3 4 →